1. Home
  2. FEIM vs PLRX Comparison

FEIM vs PLRX Comparison

Compare FEIM & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FEIM
  • PLRX
  • Stock Information
  • Founded
  • FEIM 1961
  • PLRX 2015
  • Country
  • FEIM United States
  • PLRX United States
  • Employees
  • FEIM N/A
  • PLRX N/A
  • Industry
  • FEIM Electrical Products
  • PLRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FEIM Industrials
  • PLRX Health Care
  • Exchange
  • FEIM Nasdaq
  • PLRX Nasdaq
  • Market Cap
  • FEIM 173.6M
  • PLRX 165.5M
  • IPO Year
  • FEIM N/A
  • PLRX 2020
  • Fundamental
  • Price
  • FEIM $15.24
  • PLRX $1.31
  • Analyst Decision
  • FEIM
  • PLRX Hold
  • Analyst Count
  • FEIM 0
  • PLRX 10
  • Target Price
  • FEIM N/A
  • PLRX $9.79
  • AVG Volume (30 Days)
  • FEIM 63.2K
  • PLRX 1.8M
  • Earning Date
  • FEIM 03-13-2025
  • PLRX 05-05-2025
  • Dividend Yield
  • FEIM 6.50%
  • PLRX N/A
  • EPS Growth
  • FEIM 604.98
  • PLRX N/A
  • EPS
  • FEIM 2.41
  • PLRX N/A
  • Revenue
  • FEIM $65,400,999.00
  • PLRX N/A
  • Revenue This Year
  • FEIM N/A
  • PLRX N/A
  • Revenue Next Year
  • FEIM N/A
  • PLRX N/A
  • P/E Ratio
  • FEIM $6.53
  • PLRX N/A
  • Revenue Growth
  • FEIM 24.10
  • PLRX N/A
  • 52 Week Low
  • FEIM $8.62
  • PLRX $1.24
  • 52 Week High
  • FEIM $20.33
  • PLRX $16.52
  • Technical
  • Relative Strength Index (RSI)
  • FEIM 45.52
  • PLRX 26.25
  • Support Level
  • FEIM $15.17
  • PLRX $1.24
  • Resistance Level
  • FEIM $15.98
  • PLRX $1.46
  • Average True Range (ATR)
  • FEIM 0.76
  • PLRX 0.12
  • MACD
  • FEIM 0.00
  • PLRX 0.21
  • Stochastic Oscillator
  • FEIM 16.86
  • PLRX 12.76

About FEIM Frequency Electronics Inc.

Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Share on Social Networks: